{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001878313","name":"MAIA Biotechnology, Inc.","summary":"MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Its lead asset, ateganosine (THIO, 6-thio-dG), is an investigational dual mechanism drug candidate targeting telomeres and inducing immunogenicity. Ateganosine is being evaluated primarily in Non-Small Cell Lung Cancer (NSCLC) in Phase 2 (THIO-101) and Phase 3 (THIO-104) trials, with planned Phase 2 trials in hepatocellular carcinoma, colorectal cancer, and small cell lung cancer.","people":[],"products":[{"name":"Ateganosine (THIO, 6-thio-dG, 6-thio-2'-deoxyguanosine)","type":"platform","description":"Investigational telomere-targeting immunotherapy drug candidate for cancer, primarily advanced NSCLC, with dual mechanism of action incorporating telomere targeting and immunogenicity."}],"partnerships":[{"partner_name":"Regeneron","partnership_type":"development","description":"Clinical supply agreement for cemiplimab (Libtayo) at no cost for THIO-101 trial; Regeneron granted exclusive development rights for NSCLC combination with PD-1 inhibitors during study period.","start_date":null},{"partner_name":"BeOne Medicines","partnership_type":"development","description":"Planned use of BeOne Medicines' immune checkpoint inhibitor tislelizumab in Phase 2 trials for HCC, CRC, and SCLC.","start_date":null},{"partner_name":"National Cancer Institute (NCI)","partnership_type":"development","description":"Earlier clinical trials sponsored by NCI in the 1970s provided historical safety data referenced for ateganosine dosing rationale.","start_date":null}],"affiliations":[],"origin":{"leaf":"394d3c99f50422fcd0ee4054aabbab3b7d8bc1b6e6a93b232ab0248b9248348b","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"df0b8c1ab568b6986ca9008ffbb64e273e909e87cca3be60594e27bafefc0169","parent":"706bcba4100858c54036e86a77e72cdcfb7f08567bcd68f2cf92e9a6c4ea3a3b","source":"0001493152-26-012088","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":102,"hourly_limit":500,"remaining":398,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}